The split in outlook underscores Lilly's strong position in the obesity market, underpinned by more effective drugs and its direct-to-consumer sales strategy.
Source: CNBC
Thursday, 05. February 2026
Share:
04. February 2026 20:51
Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
